Lineage Cell Therapeutics, Inc. (LCTX) Stock Price & Analysis

Lineage Cell Therapeutics, Inc. (LCTX) fell 1.82% to USD 1.08 as of September 8, 2026 at 08:21 UTC, according to Nexqual real-time market data.

LCTX last closed at USD 1.08; the session ranged USD 1.08–1.11 on volume of 535,684 shares. Market capitalization is —, with a 52-week range of USD 1–2.09 (ASE). Source: Nexqual, September 8, 2026 at 08:21 UTC.

Key Statistics (as of September 8, 2026 at 08:21 UTC)

Technical Analysis (LCTX)

Nexqual's technical model rates LCTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 08:21 UTC.

From Lineage Cell Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• The AlloSCOPE Manufacturing Platform AlloSCOPE, which stands for Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering, is the name we've given to our proprietary allogeneic cell manufacturing platform.
• Cell Therapy Technology Platform AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) Platform We believe we are a leader in pluripotent, cell-based non-oncology product development, as evidenced by our proprietary directed differentiation processes for multiple cellular lineages, cell manufacturing capabilities, corporate alliances, and stage of clinical development across multiple programs.
• Approximately 85-90% of AMD patients suffer from the dry form of AMD, for which there are only two FDA approved therapeutic options at this time, pegcetacoplan injection (SYFOVRE®) and avacincaptad pegol intravitreal solution (IZERVAY™).
• This approach differs from the two FDA-approved drugs for treatment of GA secondary to AMD, pegcetacoplan injection (SYFOVRE ® ) and avacincaptad pegol intravitreal solution (IZERVAY™), and approved agents currently marketed for wet AMD, such as ranibizumab (Lucentis ® ) and aflibercept (Eylea ® ).

Partnerships

• OpRegen (also known as RG6501) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells and is being developed for the treatment of ocular disorders, including GA secondary to dry-AMD under our global Collaboration and License Agreement with Roche entered into in December 2021 (the "Roche Agreement").
• In February 2021, we announced an exclusive agreement with Neurgain Technologies, Inc. ("Neurgain"), to evaluate a novel delivery system for OPC1.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 08:21 UTC. This page is informational and not investment advice.